The aim of this review is to provide an overview of the delivery systems of chitosan-based chemotherapy agents that have been developed for the treatment of tumor cancer. Cancer treatment is a challenge that has always provided opportunities in different areas of study, due to its very complexity. Innovative options to make chemotherapy an effective treatment by targeting drugs to cancer cells through different modifications in delivery systems are being investigated. Chitosan, a biopolymer that is obtained from the partial deacetylation of chitin (the second most abundant biopolymer on earth) and is present in the exoskeleton of crustaceans, some insects, and also in the cell wall of some fungi. Chitosan has specific characteristics of solubility, functional groups in its structure, crosslinking power, affinity with other materials, biocompatibility, biodegradability, muco adhesiveness, provides bioavailability of the chemotherapeutic agent on cancer cells, without harming healthy cells. This document compiles some interesting studies on the use of chitosan in conjugation with other agents and safe materials for use in biomedicine, for the design, characterization, and development of new transport systems for chemotherapeutic agents, increasing the efficacy of this therapy in cancer treatment tumors.

Cancer and infectious diseases are two of the world’s major public health problems. Gemcitabine (GEM) is an effective chemotherapeutic agent against several types of cancer. In this study, we developed macrocapsules incorporating GEM into a chitosan matrix blended with magnetite and zeolite by ionic gelation. Physicochemical characterization was performed using HRTEM-ED, XRD, FESEM–EDS, FT-IR, TGA, encapsulation efficiency (%E.E.), and release profiles at pHs 7.4 and 5.0. Cell viability tests against A549 and H1299 cell lines, and microbiological properties against staphylococcal strains were performed. Our results revealed the successful production of hemispherical capsules with an average diameter of 1.22 mm, a rough surface, and characteristic FT-IR material interaction bands. The macrocapsules showed a high GEM encapsulation efficiency of over 86% and controlled release over 24 h. Cell viability assays revealed that similar cytotoxic effects to free GEM were achieved with a 45-fold lower GEM concentration, suggesting reduced dosing requirements and potentially fewer side effects. Additionally, the macrocapsules demonstrated potent antimicrobial activity, reducing Staphylococcus epidermidis growth by over 90%. These results highlight the macrocapsules dual role as a chemotherapeutic and antimicrobial agent, offering a promising strategy for treating lung cancer in patients at risk of infectious diseases or who are immunosuppressed.

Cancer and infectious diseases are two of the world's major public health problems. Gemcitabine (GEM) is an effective chemotherapeutic agent against several types of cancer. In this study, we developed macrocapsules by incorporating GEM into a chitosan matrix blended with magnetite and zeolite. The physico-chemical characterization of the precursor materials and the new delivery system was carried out by HRTEM-ED, XRD, FESEM-EDS, FT-IR, TGA, encapsulation efficiency (%E.E.) and release profiles at pH 7.4 and 5.0. Cell viability tests on A549 and H1299 cell lines and microbiological properties against staphylococcal strains were performed. Our results revealed the successful production of hemispherical capsules with an average diameter of 1.22 mm, a rough surface and characteristic FT-IR material interaction bands. GEM encapsulation rates exceeded 80%, and release profiles were well-controlled over 24 hours at tested pH levels. Notably, cell viability in H1299 cells was lower than the free GEM control. Moreover, the formulation exhibited potent antimicrobial activity against Staphylococcus epidermidis, highlighting its dual action as a chemotherapeutic and antimicrobial agent. This dual effect underscores the potential of these macrocapsules as innovative delivery system for treating lung cancer in patients who are also at risk of infectious diseases and who are immunosuppressed.